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Introduction
Sarcopenia as a clinical syndrome has been described as 
low muscle strength and/or low muscle quality or quantity and 
poor physical performance (1-3). Depending on the definition, 
the prevalence of sarcopenia is reported to be up to 29% 
among older community-dwelling adults and up to 33% among 
individuals living in long-term care institutions (1-3).  Several 
studies have linked sarcopenia as a clinical entity to morbidity 
and mortality, impaired physical disability, falls, fractures, poor 
quality of life, depression and hospitalization (4-11). In a recent 
review, sarcopenia, defined by computed tomography, was 
common among chronically ill hospital patients and associated 
with infectious complications, longer hospitalization, higher 
mortality and greater need for rehabilitation (12).
The relative role of various sarcopenic components as health 
predictors has raised discussion and clearly needs further 
evaluation. Special attention has been paid to the comparative 
importance of muscle loss and muscle function. Although 
both low muscle mass and poor muscle function predispose 
older adults to poor health outcomes, the associations of their 
components with aging differ (13, 14). Several studies have 
shown that mid-arm muscle and calf circumferences correlate 
with appendicular muscle mass and reflect both health and 
nutritional status and predict physical performance, health 
and survival among older people (7, 8, 15, 16). Clark and 
Manini have emphasized that the loss of muscle function 
represents a greater risk of poor health outcomes and physical 
dependence than the loss of muscle mass and that monitoring 
muscle strength has greater feasibility in everyday practice 
(17). Some studies suggest that muscle function may be a more 
powerful predictor of disability and mortality than muscle mass 
(18,19) and that reduced muscle quality has a greater impact 
on physical independence (13, 20, 21). A recent, large cross-
sectional study associated low muscle mass with a risk of losing 
physical independence at 90 years of age, but the loss of muscle 
function played a more dominant role, and the presence of both 
criteria presented the greatest risk (22).
Simultaneous obesity or lack of obesity has also often 
confounded results. For instance, it has been suggested that 
obesity combined with poor muscle function, but not with 
low muscle mass, predicts the risk of falls at older ages (23). 
According to a review of 12 prospective cohort studies, 
sarcopenic obesity was associated with a 24% increased risk 
of all-cause mortality (24). However, in a recent English 
study, sarcopenic obesity did not confer any greater risk than 
sarcopenia alone (25). The greatest mortality was observed 
when sarcopenia was associated with weight loss.
Most characteristics of sarcopenia are relatively easy to 
measure and standardize. However, obtaining an accurate 
measure of muscle mass may be a major obstacle. Magnetic 
resonance imaging (MRI), computed tomography (CT) and 
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dual energy x-ray absorptiometry (DXA) are not often available 
for large-scale population studies (1). Transportable bio-
electrical impedance analysis (BIA) estimates the volume of 
fat and lean body mass based on the relationship between the 
volume of a conductor and its electrical resistance. The method 
is not expensive, requires no specialized staff and is relatively 
easy to use in clinical practice, both on ambulatory subjects 
and hospitalized patients. Although the accuracy of the method 
has been criticized because it has been reported to overestimate 
muscle mass and underestimate fat mass (26-30), it can provide 
valid measurements (31).  Bioimpedance spectroscopy (BIS) 
uses hundreds of frequencies within a wide range, allowing the 
calculation of intracellular resistance (Ri), a measure that does 
not require data on subject characteristics or population-based 
algorithms. Ri is closely related to the intracellular water (ICW) 
compartment and may be considered a surrogate for skeletal 
muscle cell mass, as fat and bone cells have low intracellular 
water content (26). 
In order to obtain a deeper insight into the relative 
influences of sarcopenia indicators, it seems to be justifiable 
to simultaneously and repeatedly test all the characteristics of 
sarcopenia longitudinally, in sufficiently long-term studies with 
a large series of independent outcomes. For this purpose, we 
related measures of muscle mass, muscle strength, and physical 
functioning indices registered three times during the first year 
to the outcome four years later. We placed special emphasis on 





The data were derived from the Porvoo Sarcopenia and 
Nutrition Trial (ACTRN12612001253897) (32). Briefly, we 
approached the 75+ population living in Porvoo, Finland 
(N=3275) via a postal questionnaire (response rate 60.5%), and 
the research group further examined the individuals at risk of 
sarcopenia (limitations in activities of daily living, sedentary 
lifestyle, falls, exhaustion, old age, low BMI) (N= 428). Of 
these, 88 died within four years. A total of 182 randomized 
people participated in a three-armed, 12-month intervention 
trial and were re-examined at six months and at one year from 
baseline. Of these participants, 33 died before the four-year 
examination. We obtained the census status and date of death of 
the participants from the bureau of Official Statistics of Finland 
(SVT) in 2016, which is 100% complete.
Data collection and examinations
We collected demographic data and medical history 
by postal questionnaire at baseline and at four years. The 
response rate for the four-year postal questionnaire was 
79.1% (N=262/340). The questionnaires included a Finnish 
translation of the physical functioning RAND-36 (0–100 
points) (33). Morbidity was classified according to the Charlson 
Comorbidity Index (CCI) (34). 
The participants at risk of sarcopenia were examined 
clinically at a day clinic or during a home visit. We assessed 
physical performance using the short physical performance 
battery (SPPB) (35), with 0 points indicating poorest and 
12 best performance. The tests included measurements of 
walking speed (36) and the chair-stand-test (37). Muscle 
strength was assessed using a hand grip dynamometer (JAMAR 
dynamometer, Saehan Corp., Masan, Korea). Cognitive 
function was evaluated by the Minimental State Examination 
(MMSE) (38), muscle endurance by the two-minute step test 
(39), and BMI was also calculated. 
Bioimpedance spectroscopy was performed using a single-
channel, tetra polar device (SFB7, ImpediMed Ltd., Eight 
Miles Plains, Queensland, Australia) that scans 256 frequencies 
between 4 and 1000 kHz. We recorded the values without 
further software processing. Segmental calf intracellular 
resistance skeletal muscle index (CRi-SMI) was calculated 
from the BIS data of calf measurements as follows: CRi-
SMI=electrode distance2/Ricalf (cm2/Ω), using the means of 
both calves. The whole-body single frequency skeletal muscle 
index (SF-SMI) was calculated from the whole-body skeletal 
muscle mass (SMM), assessed according to Janssen et al. 
[40]. It was then transformed into the skeletal muscle index as 
follows: SF-SMI=SMM/height2. 
The survey elicited the use of home-care services.
Ethics
The study protocol was approved by the ethics committee 
for internal medicine of the hospital district of Helsinki and 
Uusimaa. We obtained informed consent from each patient 
or their next of kin.  The participants signed their informed 
consent before the start of any trial procedures. In the case of 
a participants’ cognitive decline ((MMSE) <19) (38) or poor 
capability of judgment, a proxy was invited to give consent in 
addition to the participant’s consent.
Statistics
We used SPSS software (IBM Corp. Released 2012. IBM 
SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM 
Corp.) for the statistical analyses. Continuous variables with 
normal distribution were expressed by means with standard 
deviations (SD) and those with skewed distribution by medians 
with first and fourth quartile cut-off points. For the variables 
with normal distribution, we conducted statistical comparisons 
of the groups using Student’s t-test, and for those with skewed 
distribution the Mann-Whitney U test. When appropriate, we 
used analysis of variance. The Chi-Square test was used to 
test the relationship between the two categorical variables and 
Fischer’s exact test was used when appropriate. We performed 
binary logistic regression analysis and linear regression 
analyses to assess the prognostic significance separately for 
each test variable. Age and gender were used as covariates.
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Of the 428 participants clinically examined at entry, 
88 died during the follow-up period. The mean age of the 
respondents was 83 years at entry. At four years, we sent a 
postal questionnaire to 340 survivors, which was returned 
by 262 (79.1%). Compared with the women, the men had 
more diseases (higher comorbidity index) but greater muscle 
mass and strength (Table 1). Otherwise, the differences in 
age, BMI and physical functioning between the genders were 
insignificant.
Compared with the respondents, the non-respondents (N=78) 
were sicker (CCI 2.32 vs 1.88, p=0.048), and had poorer 
performance (SPPB 7.81 vs 8.97, p<0.001), and but their 
muscle mass SF-SMI (8.16 kg/m2 vs 7.67 kg/m2, p=0.022) was 
higher at baseline. These differences were mainly due to men 
being over-presented among the non-respondents (30.0% vs 
20.1%, p=0.054).
Follow-up
The majority (N=252, 96%) of the participants still lived at 
home and 153 people (58.4%) did not use home care services 
at four years (Table 1). Three out of four (72.1%) complained 
of memory decline. Most (N=185, 70.6%) did not use walking 
aids indoors and one in two (51.5%) were able to walk outdoors 
without aids or help. A total of 32 (12%) people were not able 
to get up from a chair without assistance (hands or other person) 
and 17 (7%) did not walk outdoors at all. Of the respondents, 
98 (37%) had fallen and 15 (6%) had suffered a bone fracture 
during the previous year. Fifty-eight (22%) reported a weight 
loss of at least 3 kg during the previous three months but only 
26 (10%) regarded their general health as poor.
Table 1
Baseline characteristics (SD) of participants of follow-up study (N=262) by gender and use of home care services at four years
Variable Women (N=194) Men (N=68) P-value
Mean age (SD), years 82.4 (4.4) 83.4 (4.5) 0.248
Mean Charlson Comorbity Index (SD)  1.76 (1.6) 2.22 (1.5) 0.037
BMI, kg/m2 27.4 (4.6) 27.3 (4.2) 0.491
SPPB (0-12) 9.01 (2.4) 8.9 (3.0) 0.649
RAND-36 (0-100) 53.3 (29.2) 57.7 (29.6) 0.257
Walking speed, m/s 0.95 (0.23) 0.95 (0.30) 0.984
Two-minute step test, no 80.2 (22.5) 82.7 (23.4) 0.480
Grip strength, kg 18.3 (4.1) 28.0 (7.0) <0.001
SF-SMI, kg/m2 6.94 (0.91) 9.79 (1.09) 0.060
CRi-SMI, cm2/Ω 1.14 (0.38) 1.76 (0.51) <0.001
Non-user (N=153) User (N=109) P-value
Age, years 81.8 (4.7) 84.4 (4.7) <0.001
Mean Charlson Comorbity Index (SD)  1.75 (1.5) 2.14 (1.7) 0.053
BMI, kg/m 27.5 (4.6) 27.2 (4.4) 0.647
RAND-36 (0-100) 62.4 (24.8) 43.2 (26.3) <0.001
SPPB (0-12) 9.7 (2.2) 8.0 (2.7) <0.001
Two-minute step test, no 88.3 (24.4) 72.9 (22.6) <0.001
Grip strength, kg 20.9 (5.7) 20.6 (7.7) 0.713
MMSE (0-30) 26.2 (2.7) 25.9 (2.7) 0.362
SF-SMI, kg/m2 7.6 (1.5) 7.7 (1.7) 0.663
CRi-SMI, cm2/Ω 1.58 (0.42) 1.39 (0.44) <0.001
Charlson Comorbidity Index (SD) 1.75 (1.5) 2.14 (1.7) 0.053
BMI, kg/m 27.5 (4.6) 27.2 (4.4) 0.647
RAND-36 (0-100) 62.4 (24.8) 43.2 (26.3) <0.001
Tähän pitäisi laittaa variaabeleiden referenssit + statist. testit
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Predictors of physical functioning
Those living independently at four years had lower baseline 
BMI (26.9 vs 29.3, gender adjusted p = 0.029), and lower 
SF-SMI (7.53 kg/m2 vs 7.96 kg/m2, p = 0.039) but higher CRi-
SMI (1.56 cm2/Ω vs 1.38 cm2/Ω, p = 0.010) than the other 
participants.
The predictive value of the various sarcopenia indicators 
was first tested in relation to outdoor mobility. Table 2 shows 
that good physical functioning according to RAND-36, good 
physical performance according to SPPB, and good walking 
speed and muscle strength at baseline predicted good outdoor 
mobility in the follow-up, and that obesity and comorbidity 
had opposite relationships. The muscle mass indicators showed 
different results: CRi-SMI was a strong predictor of good 
Table 2
Age- and gender-adjusted predictors of good outdoor mobility (no aids and no help) 
Variable OR 95% CIs P-value
BMI, kg/m2 0.88 0.83 – 0.94 <0.001
Baseline RAND-36 (0-100) 1.05 1.04 – 1.06 <0.001
Charlson comorbidity Index 0.76 0.63 - 0.92 0.004
SPPB (1-12) 1.67 1.43 – 1.97 <0.001
Two-min step test. no 1.03 1.02 – 1.04 <0.001
Grip strength. kg 1.07 1.01 – 1.13 0.023
SF-SMI, kg/m2 0.74 0.55 – 0.98 0.036
CRi-SMI, cm2/Ω 2.40 1.16 – 5.01 0.009
Age and gender were forced into logistic regression analysis as covariates.
Table 3
Test variables measured during one year as age- and gender-adjusted predictors of RAND-36 index four years later
Variable Standardized beta 95%CI for beta P-Value
Charlson comorbidity index Baseline -0.10 -2.23  -0.09 0.034
SPPS (0-12) Baseline 0.33 1.73 – 3.14 <0.001
6 months 0.26 1.85 – 3.84 <0.001
12 months 0.288 2.11 – 4.04 <0.001
BMI, kg/m2 Baseline -0.21 -2.05  -0.60 <0.001
6 months -0.17 -2.36  -0.04 0.043
12 months -0.15 -2.24 - 0.10 0.072
Two-minute step test. no Baseline 0.34 0.26 – 0.39 <0.001
6 months 0.22 0.17 – 0.41 <0.001
12 months 0.23 0.18 – 0.42 <0.001
Grip strength. kg Baseline 0.16 0.09 – 0.88 0.016
6 months 0.19 -0.08 – 2.07 0.070
12 months 0.24 0.11 – 2.10 0.014
SF-SMI, kg/m2 Baseline -0.22 -7.46 - -0.51 0.025
6 months -0.20 -9.66 – 2.27 0.222
12 months -0.32 -11.62 - -0.17 0.044
CRi-SMI, cm2/Ω Baseline 0.08 -3.25 – 13.72 0.226
6 months 0.08 -9.35 – 22.67 0.412
12 months 0.04 -12.68 – 19.71 0.668
Age and gender were forced into linear regression analysis as covariates.
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outdoor mobility (OR = 2.40), whereas the association with 
SF-SMI was significantly negative (OR = 0.74, p = 0.036). 
When these measures were further adjusted for BMI, the 
predictive value of SF-SMI was 0.84 (p = 0.34) and that of CRi-
SMI rose to 3.62 (p < 0.001) (Table 2).
We then tested the associations between potential baseline 
predictors and the physical component of RAND-36 at four 
years. We used age and gender as confounders in the linear 
regression analysis (Table 3).  Again, good physical functioning 
was predicted by higher baseline SPPB, faster walking speed, 
and stronger hand grip, whereas higher BMI and higher muscle 
mass according to SF-SMI were associated with lower RAND-
36 scores. We found no association between baseline CRi-SMI 
and RAND-36 score at four years. However, when the effects 
of muscle mass indices were further adjusted for BMI, the 
negative predictive values of SF-SMI disappeared, and those of 
CRi-SMI became positive (standardized beta = 0.18, p = 0.011). 
The results were consistent for all three measurements during 
one year. (Table 3)
Use of services
At four years, 69 (26%) people (33 men and 36 women) 
regularly used either municipal or private home care services. 
These users were older, had more diseases and reported poorer 
physical functioning than the non-users.  Neither the grip 
strength nor the muscle mass indictor SF-SMI of the groups 
differed, but CRi-SMI was lower among the users than the 
non-users. The significance of the differing characteristics was 
tested more closely using binary logistic regression analysis, 
which used age and gender as covariates (Table 4). Again, 
Table 4
Age- and gender-adjusted predictors of use of home care services
Variable OR 95% CIs P-value
Baseline RAND-36 (0-100) 0.97 0.96 –0.98 <0.001
Charlson comorbidity Index 1.17 0.99 – 1.38 0.057
SPPB (1-12) 0.79 0.70 – 0.88 <0.001
Two-minute step test. no 0.98 0.97 – 0.99 <0.001
CRi-SMI, cm2/Ω 0.37 0.18 – 0.74 <0.001
Age and gender were forced into logistic regression analysis as covariates.
Table 5
Comparison of BMI and skeletal muscle indices as predictors of physical functioning at four-year follow-up
Variable At home without helpsa Physical functioning of RAND-36b
OR 95% CIs P-value Standardized beta 95%CI for beta P-value
Unadjusted
BMI, kg/m2 0.94 0.88 - 0.99 0.031 -0.21 -2.09  -0.56 <0.001
SF-SMI, kg/m2 0.84 0.71- 0.99 0.045 -0.03 -2.88 – 1.62 0.584
CRi-SMI, cm2/Ω 2.52 1.32 – 4.83 0.005 0.16 2.33 – 18.9 0.011
Adjusted for age and gender
BMI, kg/m2 0.93 0.88 – 0.99 0.025 -0.20 -2.01  -0.56 <0.001
SF-SMI 0.74 0.55 – 0.98 0.036 -0.21 -7.31 - -9.38 0.030
CRi-SMI, cm2/Ω 2.41 1.16 – 5.01 0.019 0.07 -4.10 – 13.01 0.306
Adjusted for age, gender and comorbidity
BMI, kg/m2 0.95 0.89 – 1.01 0.088 -0.18 -1.86 - -0.39 0.003
SF-SMI, kg/m2 0.79 0.058 – 1.05 0.098 -0.17 -6.61 – 0.37 0.079
CRi-SMI, cm2/Ω 2.43 1.16 – 5.13 0.019 0.07 -4.11 – 12.77 0.314
Adjusted for age, gender, comorbidity and BMI
SF-SMI, kg/m2 0.86 0.60 – 1.24 0.412 -0.01 -4.37 – 4.10 0.951
CRi-SMI, cm2/Ω 3.47 1.55 – 7.76 0.002 0.15 1.07-18.63 0.028
a. Binary logistic regression analysis.  b. Linear regression analysis.
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the indicators of good physical functioning and performance 
(RAND-36, SPPB) and good mobility retained highly 
significant predictive value. This also held true for CRi-SMI.  
Figure 1
Probability of independently living at home by 10% differences 
in muscle mass indices (CRI-SMI and SF-SMI) and body 
mass index (BMI). The data are adjusted for age, gender and 
comorbidity
Comparison of BMI and skeletal muscle indices
Finally, we compared the predictive values of BMI and 
two skeletal muscle indices in relation to the use of help and 
physical functioning (Table 5). Again, both BMI and SF-SMI 
were negatively associated and CRi-SMI positively associated 
with the prognosis of physical functioning according to RAND-
36. When adjusted for age, gender and comorbidity, the 
negative influence of BMI remained virtually unchanged, but 
the positive association with CRi-SMI accentuated. The latter 
was also highly predicted after further controlling for BMI. Due 
to the large differences in the scales of BMI and muscle mass 
measures, we used percentage distributions (mean =100) for 
further comparisons (Fig. 1). When controlled for age, gender 
and comorbidity, a 10% difference in Cri-SMI was associated 
with a 4% better probability of independently living at home, 
whereas the respective figures for SF-SMI and BMI were -18% 
and -14%.   
Discussion
This longitudinal study shows that good baseline physical 
performance and functioning, stronger hand grip strength, 
higher muscle mass indices and lower BMI predict better 
physical performance and the need for care of older people at 
risk of sarcopenia. We also found interesting differences in the 
predictive significance of various methods in the assessment of 
muscle mass. 
The results do not challenge earlier observations concerning 
obesity or hand grip strength (41) but provide new insights 
into the differences of the two muscle mass indices and their 
interplay with BMI. Both high BMI and high SF-SMI predicted 
consistently poorer outcomes, whereas high CRi-SMI was 
associated with good mobility and physical functioning 
and predicted independent living at home. In this respect, 
the contradictory results of CRi-SMI and SF-SMI deserve 
special attention. Closer analyses revealed a relatively strong 
positive correlation between BMI and SF-SMI (age- and gender 
adjusted rho = 0.573, p < 0.001) at baseline (unpublished data). 
Thus, the clearly negative influence of high BMI overruns 
the possible beneficial effects of whole-body muscle mass 
measured by SF-SMI in this population sample. This was, in 
fact, verified by adjusting the effects of muscle mass indices 
for BMI, which partly abolished the negative associations of 
SF-SMI and accentuated the positive associations of CRi-SMI. 
The observation that high BMI and low CRi-SMI were both 
strong, independent predictors of poor physical functioning 
in old age accord well with the concept of sarcopenic obesity, 
which has become increasingly important in the aging 
population (24, 25, 42). Evidence is also increasing that 
sarcopenic obesity is also associated more with mortality and 
cardiovascular risk factors than with sarcopenia or obesity alone 
(24, 26, 44).
The study clearly showed the superiority of CRi-SMI over 
SF-SMI as a positive mobility predictor among older people. 
This observation is not surprising, as the former measures the 
muscle mass of the lower limbs, whereas the latter reflects 
whole-body muscle mass. It is conceivable that the lower-limb 
muscles are more important for mobility than whole-body 
muscle mass. The present results accord well with earlier 
observations that have shown close associations between Cri-
SMI and the daily living activities and mobility of typical 
nursing home residents (44). Our observations also support 
the criticism of the validity of SF-SMI measurements of older 
people (26-30).
The representativeness of the population sample, the serial 
measures of the key indicators, the clear end-points and the 
consistency of the results are this study’s major strengths. Its 
weaknesses are its lacking DEXA or MRI measurements.
Conclusion Lower limb CRi-SMI is an independent long-
term predictor of the outdoor mobility and physical functioning 
of older sarcopenic home-dwelling people, whereas the 
predictive value remains insignificant for whole-body muscle 
mass index (SF-SMI), which is partly masked by negative 
influences of high BMI. 
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